

Institut für Lungenforschung und pneumologische Onkologie

Institutsleitung: Prim. Priv. Doz. Dr. Arschang Valipour

Wissenschaftliche Publikationen 2021:

Top 5 Publikationen des Instituts im Jahr 2021:

- Illini O, Hochmair MJ, Fabikan H, Weinlinger C, Tufman A, Swalduz A, Lamberg K, Hashemi SMS, Huemer F, Vikström A, Wermke M, Absenger G, Addeo A, Banerji S, Calles A, Clarke S, Di Maio M, Durand A, Duruisseaux M, Itchins M, Kääränen OS, Krenn F, Laack E, de Langen AJ, Mohorcic K, Pall G, Passaro A, Prager G, Rittmeyer A, Rothenstein J, Schumacher M, Wöll E, Valipour A. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. *Ther Adv Med Oncol*. 2021 Jun 11;13:17588359211019675.
- Pison C, Shah PL, Slebos DJ, Ninane V, Janssens W, Perez T, Kessler R, Deslee G, Garner JL, Hartman JE, Degano B, Mayr A, Mayse M, Peterson AD, Valipour A. Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes. *Respir Res*. 2021 Feb 19;22(1):62. Erratum in: *Respir Res*. 2021 Mar 15;22(1):83.
- Urban MH, Stojkovic S, Demyanets S, Hengstenberg C, Valipour A, Wojta J, Burghuber OC. Soluble ST2 and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease-A 10-Year Cohort Study. *J Clin Med*. 2021 Dec 23;11(1):56.
- Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Filip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. *J Thorac Oncol*. 2021 Dec;16(12):2091-2108
- Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Filip E, Speranza G, De Angelis F, Dómine M, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Kurata T, Yang J, Pietanza MC, Souza F, Garassino MC. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. *Ann Oncol*. 2021 Jul;32(7):881-895.

Weitere Publikationen unter:

www.karl-landsteiner.at/institute-lungenforschung_pneumologische_onkologie.html